value of bta , page-16

This would be one of Biota's "value inflection points" that they talk about, and a lani deal would fit with the philosophy. I reckon big pharma would be all over Biota right now. If we play hardball on a deal, there is the threat of a take-over. There could be a deal done during an offer, or competing take-overs. Anything that locks GSK out would be good.

All that could be very interesting, but a take-over is probably our least desired outcome.